WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 205800
Description: Domatinostat, also known as 4SC-202, is an orally bioavailable benzamide and inhibitor of human class I histone deacetylases (HDACs) isoenzymes 1, 2 and 3, with potential antineoplastic activity. HDAC inhibitor 4SC-202 selectively binds to and inhibits class I HDACs leading to an accumulation of highly acetylated histones. This may result in an induction of chromatin remodeling, the selective transcription of tumor suppressor genes, and the tumor suppressor protein-mediated inhibition of tumor cell division and eventually the induction of tumor cell apoptosis. This may inhibit tumor cell proliferation in susceptible tumor cells. HDACs, upregulated in many tumor types, are a class of enzymes that deacetylate chromatin histone proteins.
MedKoo Cat#: 205800
Chemical Formula: C23H21N5O3S
Exact Mass: 447.13651
Molecular Weight: 447.51
Elemental Analysis: C, 61.73; H, 4.73; N, 15.65; O, 10.73; S, 7.17
Synonym: 4SC202; 4SC-202; 4SC 202; domatinostat;
IUPAC/Chemical Name: (E)-N-(2-aminophenyl)-3-(1-((4-(1-methyl-1H-pyrazol-4-yl)phenyl)sulfonyl)-1H-pyrrol-3-yl)acrylamide.
InChi Key: IAVXAZDVNICKFJ-ICSBZGNSSA-N
InChi Code: InChI=1S/C23H21N5O3S.C7H8O3S/c1-27-16-19(14-25-27)18-7-9-20(10-8-18)32(30,31)28-13-12-17(15-28)6-11-23(29)26-22-5-3-2-4-21(22)24;1-6-2-4-7(5-3-6)11(8,9)10/h2-16H,24H2,1H3,(H,26,29);2-5H,1H3,(H,8,9,10)/b11-6+;
SMILES Code: O=C(NC1=CC=CC=C1N)/C=C/C2=CN(S(=O)(C3=CC=C(C4=CN(C)N=C4)C=C3)=O)C=C2.O=S(C5=CC=C(C)C=C5)(O)=O
4SC-202 is an orally administered selective class I HDAC inhibitor. 4SC-202 demonstrates a particularly strong anti-mitotic activity. 4SC-202 enables a dual attack on malignant cancer cells and is therefore not a back-up compound for resminostat. Its strong, specific anti-mitotic effect could make this candidate particularly suitable for the treatment of cancer types that exhibit high rates of cell division. 4SC-202, currently being developed by A German Company called 4SC, is in the Phase I TOPAS study in order to evaluate the safety, pharmacokinetics and clinical efficacy of the orally administered compound in patients with advanced hematological indications, including acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL), multiple myeloma (MM), myelodysplastic syndrome (MDS) and lymphomas (source: http://www.4sc.de/product-pipeline/clinical/4SC-202).